Overviewing T-Cell Engager Success in Autoimmunity & Taking Learnings From Oncology For Efficacy, Safety & Smarter Design
Time: 9:00 am
day: Day One
Details:
- Gaining a high-level overview of the current TCE pipeline in autoimmunity, including lessons learned from oncology programs and key distinctions in target biology and patient needs
- Exploring how biotech and pharmaceutical companies are repurposing or adapting B-cell and plasma-cell depleting assets originally built for oncology for use in RA, lupus, and other autoimmune diseases
- Investigating real-world efficacy and safety data from early clinical and preclinical programs (e.g., blinatumomab, teclistamab) to assess how well TCEs are performing against the higher bar of autoimmune disease
- Evaluate design principles driving optimal performance in autoimmunity, from affinity tuning and half-life engineering to format selection and target prioritization (CD19, CD20, CD38, BCMA, etc.)
